KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income: 2013-2025

Historic Net Income for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Net Income fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • Xenon Pharmaceuticals' Net Income amounted to -$90.9 million in Q3 2025, which was down 7.31% from -$84.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Net Income high stood at -$15.4 million for Q3 2021, and its period low was -$90.9 million during Q3 2025.
  • Its 3-year average for Net Income is -$61.0 million, with a median of -$57.9 million in 2024.
  • Data for Xenon Pharmaceuticals' Net Income shows a maximum YoY tumbled of 12,533.71% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Net Income stood at -$25.6 million in 2021, then plummeted by 46.45% to -$37.4 million in 2022, then decreased by 19.51% to -$44.7 million in 2023, then plummeted by 77.77% to -$79.5 million in 2024, then slumped by 44.76% to -$90.9 million in 2025.
  • Its Net Income stands at -$90.9 million for Q3 2025, versus -$84.7 million for Q2 2025 and -$65.0 million for Q1 2025.